Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated on: 04 April, 2025
Author: Getaka|Social: Getaka Financial Technology X (Earlier Twitter) Profile Getaka Financial Technology LinkedIn Logo
Stock Ticker - BSE: 531278 | NSE: ELIXIR

Elixir Capital Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: April 4, 2025, 11:18 pm

Market Cap 77.2 Cr.
Current Price 133
High / Low 351/78.0
Stock P/E3.29
Book Value 107
Dividend Yield0.94 %
ROCE36.8 %
ROE50.0 %
Face Value 10.0
PEG Ratio0.16

Stock P/E, Current Price, and Intrinsic Value Over Time

View Share Price Target for Elixir Capital Ltd

Competitors of Elixir Capital Ltd

Stock Name Market Cap Current Price High / Low Stock P/E Book Value Dividend Yield ROCE ROE Face Value
MKVentures Capital Ltd 550 Cr. 1,431 2,800/1,21226.7 2670.07 %20.6 %33.6 % 10.0
Modern Shares & Stockbrokers Ltd 14.6 Cr. 49.8 69.4/36.041.7 43.90.00 %4.33 %3.24 % 10.0
Monarch Networth Capital Ltd 2,577 Cr. 328 501/22616.6 93.00.15 %51.8 %43.4 % 10.0
Monotype India Ltd 52.0 Cr. 0.74 2.42/0.636.51 0.130.00 %438 %% 1.00
Multipurpose Trading & Agencies Ltd 4.85 Cr. 9.79 13.3/7.9325.5 10.20.00 %4.44 %3.91 % 10.0
Industry Average6,715.03 Cr1,388.2484.405,208.090.37%18.65%17.36%7.36

All Competitor Stocks of Elixir Capital Ltd

Quarterly Result

MetricDec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024
Sales 1.019.40-3.537.800.08-0.604.756.095.9115.8114.7218.566.04
Expenses 0.931.711.341.531.311.511.571.681.622.413.043.003.70
Operating Profit 0.087.69-4.876.27-1.23-2.113.184.414.2913.4011.6815.562.34
OPM % 7.92%81.81%80.38%-1,537.50%66.95%72.41%72.59%84.76%79.35%83.84%38.74%
Other Income 0.081.080.280.050.170.240.340.890.221.200.270.160.22
Interest 0.410.280.220.280.330.300.340.400.330.450.430.560.66
Depreciation 0.090.100.070.080.080.100.080.090.080.090.070.090.08
Profit before tax -0.348.39-4.885.96-1.47-2.273.104.814.1014.0611.4515.071.82
Tax % -105.88%19.19%1.43%6.04%-2.72%16.74%1.61%15.38%22.44%24.32%24.98%25.08%34.62%
Net Profit 0.016.79-4.955.61-1.43-2.653.064.083.1910.638.5911.301.19
EPS in Rs 0.038.44-8.5328.98-1.77-3.383.895.394.0713.5410.9414.411.52

Last Updated: February 28, 2025, 11:53 am

Below is a detailed analysis of the quarterly data for Elixir Capital Ltd based on the most recent figures (Dec 2024) and their trends compared to the previous period:

  • For Sales, as of Dec 2024, the value is ₹6.04 Cr.. The value appears to be declining and may need further review. It has decreased from 18.56 Cr. (Sep 2024) to ₹6.04 Cr., marking a decrease of 12.52 Cr..
  • For Expenses, as of Dec 2024, the value is ₹3.70 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 3.00 Cr. (Sep 2024) to ₹3.70 Cr., marking an increase of 0.70 Cr..
  • For Operating Profit, as of Dec 2024, the value is ₹2.34 Cr.. The value appears to be declining and may need further review. It has decreased from 15.56 Cr. (Sep 2024) to ₹2.34 Cr., marking a decrease of 13.22 Cr..
  • For OPM %, as of Dec 2024, the value is 38.74%. The value appears to be declining and may need further review. It has decreased from 83.84% (Sep 2024) to 38.74%, marking a decrease of 45.10%.
  • For Other Income, as of Dec 2024, the value is ₹0.22 Cr.. The value appears strong and on an upward trend. It has increased from 0.16 Cr. (Sep 2024) to ₹0.22 Cr., marking an increase of 0.06 Cr..
  • For Interest, as of Dec 2024, the value is ₹0.66 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.56 Cr. (Sep 2024) to ₹0.66 Cr., marking an increase of 0.10 Cr..
  • For Depreciation, as of Dec 2024, the value is ₹0.08 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.09 Cr. (Sep 2024) to ₹0.08 Cr., marking a decrease of 0.01 Cr..
  • For Profit before tax, as of Dec 2024, the value is ₹1.82 Cr.. The value appears to be declining and may need further review. It has decreased from 15.07 Cr. (Sep 2024) to ₹1.82 Cr., marking a decrease of 13.25 Cr..
  • For Tax %, as of Dec 2024, the value is 34.62%. The value appears to be increasing, which may not be favorable. It has increased from 25.08% (Sep 2024) to 34.62%, marking an increase of 9.54%.
  • For Net Profit, as of Dec 2024, the value is ₹1.19 Cr.. The value appears to be declining and may need further review. It has decreased from 11.30 Cr. (Sep 2024) to ₹1.19 Cr., marking a decrease of 10.11 Cr..
  • For EPS in Rs, as of Dec 2024, the value is 1.52. The value appears to be declining and may need further review. It has decreased from 14.41 (Sep 2024) to 1.52, marking a decrease of 12.89.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: March 15, 2025, 3:39 am

MetricMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024TTM
Sales 2412412104-0202543555
Expenses 12223434566712
Operating Profit 021021060-41519-12743
OPM % 23%56%85%49%79%63%9%77%77%-32%79%78%
Other Income -0-0-02000000012
Interest 0000000012122
Depreciation 0000000000000
Profit before tax 029396-0-51417-32642
Tax % 467%30%29%24%25%28%-10%10%11%24%28%20%
Net Profit -017274-0-4913-32132
EPS in Rs -0.241.408.432.8911.895.36-0.36-6.6015.7222.37-5.9136.1240.41
Dividend Payout % -1,032%121%20%12%11%23%-345%-19%8%6%-21%3%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2014-20152015-20162016-20172017-20182018-20192020-20212021-20222022-20232023-2024
YoY Net Profit Growth (%)600.00%-71.43%250.00%-42.86%-100.00%325.00%44.44%-123.08%800.00%
Change in YoY Net Profit Growth (%)0.00%-671.43%321.43%-292.86%-57.14%425.00%-280.56%-167.52%923.08%

Elixir Capital Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 9 years from 2014-2015 to 2023-2024.

Growth

Compounded Sales Growth
10 Years:25%
5 Years:56%
3 Years:21%
TTM:241%
Compounded Profit Growth
10 Years:38%
5 Years:151%
3 Years:31%
TTM:330%
Stock Price CAGR
10 Years:7%
5 Years:29%
3 Years:48%
1 Year:52%
Return on Equity
10 Years:19%
5 Years:23%
3 Years:27%
Last Year:50%

Last Updated: Unknown

Balance Sheet

Last Updated: January 13, 2025, 1:48 pm

MonthMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Sep 2024
Equity Capital 6666666666666
Reserves 10101314182120152331284356
Borrowings 12122211171872422
Other Liabilities 6798111212172728262437
Total Liabilities 232428303640383873836896122
Fixed Assets 6665555444433
CWIP 1000000000000
Investments 2111000101312111212
Other Assets 141722243235342456675381106
Total Assets 232428303640383873836896122

Below is a detailed analysis of the balance sheet data for Elixir Capital Ltd based on the most recent figures (Sep 2024) and their trends compared to the previous period:

  • For Equity Capital, as of Sep 2024, the value is ₹6.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 6.00 Cr..
  • For Reserves, as of Sep 2024, the value is ₹56.00 Cr.. The value appears strong and on an upward trend. It has increased from 43.00 Cr. (Mar 2024) to ₹56.00 Cr., marking an increase of 13.00 Cr..
  • For Borrowings, as of Sep 2024, the value is ₹22.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 24.00 Cr. (Mar 2024) to ₹22.00 Cr., marking a decrease of 2.00 Cr..
  • For Other Liabilities, as of Sep 2024, the value is ₹37.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 24.00 Cr. (Mar 2024) to ₹37.00 Cr., marking an increase of 13.00 Cr..
  • For Total Liabilities, as of Sep 2024, the value is ₹122.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 96.00 Cr. (Mar 2024) to ₹122.00 Cr., marking an increase of 26.00 Cr..
  • For Fixed Assets, as of Sep 2024, the value is ₹3.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 3.00 Cr..
  • For CWIP, as of Sep 2024, the value is ₹0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
  • For Investments, as of Sep 2024, the value is ₹12.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 12.00 Cr..
  • For Other Assets, as of Sep 2024, the value is ₹106.00 Cr.. The value appears strong and on an upward trend. It has increased from 81.00 Cr. (Mar 2024) to ₹106.00 Cr., marking an increase of 25.00 Cr..
  • For Total Assets, as of Sep 2024, the value is ₹122.00 Cr.. The value appears strong and on an upward trend. It has increased from 96.00 Cr. (Mar 2024) to ₹122.00 Cr., marking an increase of 26.00 Cr..

Notably, the Reserves (56.00 Cr.) exceed the Borrowings (22.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Reserves and Borrowings Chart

Cash Flow

MonthMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Cash from Operating Activity +0-011-32213-256-17
Cash from Investing Activity +-10-0-23-20-9-3022
Cash from Financing Activity +1-0-11-0-0-2-114-2-1214
Net Cash Flow0-001-001293-5-1

Free Cash Flow

MonthMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Free Cash Flow-1.000.009.000.008.004.00-1.00-5.00-2.001.00-8.003.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Debtor Days45901362-2,64605212
Inventory Days-7,419
Days Payable
Cash Conversion Cycle45901362-10,06505212
Working Capital Days1,6708954551,3826999782,5353,0933884311,685598
ROCE %1%7%38%6%29%16%-0%-13%33%29%-2%37%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthMar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024
Promoters71.29%71.29%71.29%71.29%71.29%71.29%71.29%71.29%71.29%71.29%71.29%71.29%
Public28.71%28.71%28.70%28.71%28.70%28.71%28.71%28.71%28.71%28.71%28.70%28.71%
No. of Shareholders2,4432,5612,6283,5163,4693,3333,4693,3253,1873,3973,6974,481

Shareholding Pattern Chart

No. of Shareholders

This stock is not held by any mutual fund

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 24Mar 23Mar 22Mar 21Mar 20
FaceValue 10.0010.0010.0010.0010.00
Basic EPS (Rs.) 26.89-4.2016.5415.72-6.61
Diluted EPS (Rs.) 26.89-4.2016.5415.72-6.61
Cash EPS (Rs.) 36.70-5.3223.0021.78-8.20
Book Value[Excl.RevalReserv]/Share (Rs.) 117.5583.1490.7470.0750.74
Book Value[Incl.RevalReserv]/Share (Rs.) 117.5583.1490.7470.0750.74
Revenue From Operations / Share (Rs.) 56.076.4839.9233.12-1.06
PBDIT / Share (Rs.) 47.25-2.0632.8025.90-7.03
PBIT / Share (Rs.) 46.67-2.6432.1725.19-7.72
PBT / Share (Rs.) 44.94-4.5929.3023.55-8.05
Net Profit / Share (Rs.) 36.11-5.9022.3721.07-8.89
NP After MI And SOA / Share (Rs.) 26.89-4.2016.5415.72-6.61
PBDIT Margin (%) 84.27-31.8282.1678.20662.48
PBIT Margin (%) 83.23-40.7580.5876.05727.34
PBT Margin (%) 80.14-70.8573.4071.10758.25
Net Profit Margin (%) 64.40-91.1156.0463.62837.46
NP After MI And SOA Margin (%) 47.96-64.8041.4247.47622.48
Return on Networth / Equity (%) 32.22-7.2025.7631.86-18.69
Return on Capital Employeed (%) 39.68-3.1735.4335.89-15.13
Return On Assets (%) 16.19-3.6011.6112.52-9.95
Long Term Debt / Equity (X) 0.000.000.000.000.01
Total Debt / Equity (X) 0.480.210.470.600.06
Asset Turnover Ratio (%) 0.390.050.290.34-0.01
Current Ratio (X) 2.522.812.311.912.87
Quick Ratio (X) 0.581.200.950.821.96
Dividend Payout Ratio (NP) (%) 6.32-40.5410.2911.05-26.31
Dividend Payout Ratio (CP) (%) 6.19-47.029.9110.58-29.37
Earning Retention Ratio (%) 93.68140.5489.7188.95126.31
Cash Earning Retention Ratio (%) 93.81147.0290.0989.42129.37
Interest Coverage Ratio (X) 18.02-1.0611.4415.81-21.43
Interest Coverage Ratio (Post Tax) (X) 14.43-2.038.8013.86-26.09
Enterprise Value (Cr.) 85.0330.5139.1932.7227.02
EV / Net Operating Revenue (X) 2.618.111.691.70-43.86
EV / EBITDA (X) 3.10-25.502.062.18-6.62
MarketCap / Net Operating Revenue (X) 1.585.280.950.86-34.62
Retention Ratios (%) 93.67140.5489.7088.94126.31
Price / BV (X) 1.060.580.590.571.04
Price / Net Operating Revenue (X) 1.585.280.950.86-34.64
EarningsYield 0.30-0.120.430.54-0.17

After reviewing the key financial ratios for Elixir Capital Ltd, here is a detailed analysis based on the latest available data and recent trends:

  • For FaceValue, as of Mar 24, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 23) which recorded 10.00.
  • For Basic EPS (Rs.), as of Mar 24, the value is 26.89. This value is within the healthy range. It has increased from -4.20 (Mar 23) to 26.89, marking an increase of 31.09.
  • For Diluted EPS (Rs.), as of Mar 24, the value is 26.89. This value is within the healthy range. It has increased from -4.20 (Mar 23) to 26.89, marking an increase of 31.09.
  • For Cash EPS (Rs.), as of Mar 24, the value is 36.70. This value is within the healthy range. It has increased from -5.32 (Mar 23) to 36.70, marking an increase of 42.02.
  • For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 117.55. It has increased from 83.14 (Mar 23) to 117.55, marking an increase of 34.41.
  • For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 117.55. It has increased from 83.14 (Mar 23) to 117.55, marking an increase of 34.41.
  • For Revenue From Operations / Share (Rs.), as of Mar 24, the value is 56.07. It has increased from 6.48 (Mar 23) to 56.07, marking an increase of 49.59.
  • For PBDIT / Share (Rs.), as of Mar 24, the value is 47.25. This value is within the healthy range. It has increased from -2.06 (Mar 23) to 47.25, marking an increase of 49.31.
  • For PBIT / Share (Rs.), as of Mar 24, the value is 46.67. This value is within the healthy range. It has increased from -2.64 (Mar 23) to 46.67, marking an increase of 49.31.
  • For PBT / Share (Rs.), as of Mar 24, the value is 44.94. This value is within the healthy range. It has increased from -4.59 (Mar 23) to 44.94, marking an increase of 49.53.
  • For Net Profit / Share (Rs.), as of Mar 24, the value is 36.11. This value is within the healthy range. It has increased from -5.90 (Mar 23) to 36.11, marking an increase of 42.01.
  • For NP After MI And SOA / Share (Rs.), as of Mar 24, the value is 26.89. This value is within the healthy range. It has increased from -4.20 (Mar 23) to 26.89, marking an increase of 31.09.
  • For PBDIT Margin (%), as of Mar 24, the value is 84.27. This value is within the healthy range. It has increased from -31.82 (Mar 23) to 84.27, marking an increase of 116.09.
  • For PBIT Margin (%), as of Mar 24, the value is 83.23. This value exceeds the healthy maximum of 20. It has increased from -40.75 (Mar 23) to 83.23, marking an increase of 123.98.
  • For PBT Margin (%), as of Mar 24, the value is 80.14. This value is within the healthy range. It has increased from -70.85 (Mar 23) to 80.14, marking an increase of 150.99.
  • For Net Profit Margin (%), as of Mar 24, the value is 64.40. This value exceeds the healthy maximum of 10. It has increased from -91.11 (Mar 23) to 64.40, marking an increase of 155.51.
  • For NP After MI And SOA Margin (%), as of Mar 24, the value is 47.96. This value exceeds the healthy maximum of 20. It has increased from -64.80 (Mar 23) to 47.96, marking an increase of 112.76.
  • For Return on Networth / Equity (%), as of Mar 24, the value is 32.22. This value is within the healthy range. It has increased from -7.20 (Mar 23) to 32.22, marking an increase of 39.42.
  • For Return on Capital Employeed (%), as of Mar 24, the value is 39.68. This value is within the healthy range. It has increased from -3.17 (Mar 23) to 39.68, marking an increase of 42.85.
  • For Return On Assets (%), as of Mar 24, the value is 16.19. This value is within the healthy range. It has increased from -3.60 (Mar 23) to 16.19, marking an increase of 19.79.
  • For Long Term Debt / Equity (X), as of Mar 24, the value is 0.00. This value is below the healthy minimum of 0.2. There is no change compared to the previous period (Mar 23) which recorded 0.00.
  • For Total Debt / Equity (X), as of Mar 24, the value is 0.48. This value is within the healthy range. It has increased from 0.21 (Mar 23) to 0.48, marking an increase of 0.27.
  • For Asset Turnover Ratio (%), as of Mar 24, the value is 0.39. It has increased from 0.05 (Mar 23) to 0.39, marking an increase of 0.34.
  • For Current Ratio (X), as of Mar 24, the value is 2.52. This value is within the healthy range. It has decreased from 2.81 (Mar 23) to 2.52, marking a decrease of 0.29.
  • For Quick Ratio (X), as of Mar 24, the value is 0.58. This value is below the healthy minimum of 1. It has decreased from 1.20 (Mar 23) to 0.58, marking a decrease of 0.62.
  • For Dividend Payout Ratio (NP) (%), as of Mar 24, the value is 6.32. This value is below the healthy minimum of 20. It has increased from -40.54 (Mar 23) to 6.32, marking an increase of 46.86.
  • For Dividend Payout Ratio (CP) (%), as of Mar 24, the value is 6.19. This value is below the healthy minimum of 20. It has increased from -47.02 (Mar 23) to 6.19, marking an increase of 53.21.
  • For Earning Retention Ratio (%), as of Mar 24, the value is 93.68. This value exceeds the healthy maximum of 70. It has decreased from 140.54 (Mar 23) to 93.68, marking a decrease of 46.86.
  • For Cash Earning Retention Ratio (%), as of Mar 24, the value is 93.81. This value exceeds the healthy maximum of 70. It has decreased from 147.02 (Mar 23) to 93.81, marking a decrease of 53.21.
  • For Interest Coverage Ratio (X), as of Mar 24, the value is 18.02. This value is within the healthy range. It has increased from -1.06 (Mar 23) to 18.02, marking an increase of 19.08.
  • For Interest Coverage Ratio (Post Tax) (X), as of Mar 24, the value is 14.43. This value is within the healthy range. It has increased from -2.03 (Mar 23) to 14.43, marking an increase of 16.46.
  • For Enterprise Value (Cr.), as of Mar 24, the value is 85.03. It has increased from 30.51 (Mar 23) to 85.03, marking an increase of 54.52.
  • For EV / Net Operating Revenue (X), as of Mar 24, the value is 2.61. This value is within the healthy range. It has decreased from 8.11 (Mar 23) to 2.61, marking a decrease of 5.50.
  • For EV / EBITDA (X), as of Mar 24, the value is 3.10. This value is below the healthy minimum of 5. It has increased from -25.50 (Mar 23) to 3.10, marking an increase of 28.60.
  • For MarketCap / Net Operating Revenue (X), as of Mar 24, the value is 1.58. This value is within the healthy range. It has decreased from 5.28 (Mar 23) to 1.58, marking a decrease of 3.70.
  • For Retention Ratios (%), as of Mar 24, the value is 93.67. This value exceeds the healthy maximum of 70. It has decreased from 140.54 (Mar 23) to 93.67, marking a decrease of 46.87.
  • For Price / BV (X), as of Mar 24, the value is 1.06. This value is within the healthy range. It has increased from 0.58 (Mar 23) to 1.06, marking an increase of 0.48.
  • For Price / Net Operating Revenue (X), as of Mar 24, the value is 1.58. This value is within the healthy range. It has decreased from 5.28 (Mar 23) to 1.58, marking a decrease of 3.70.
  • For EarningsYield, as of Mar 24, the value is 0.30. This value is below the healthy minimum of 5. It has increased from -0.12 (Mar 23) to 0.30, marking an increase of 0.42.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value of Elixir Capital Ltd as of April 4, 2025 is: 142.14

Calculation basis:

  • Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

As of April 4, 2025, Elixir Capital Ltd is Undervalued by 6.87% compared to the current share price 133.00

Intrinsic Value of Elixir Capital Ltd as of April 4, 2025 is: 171.68

Calculation basis:

  • Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
  • EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.

As of April 4, 2025, Elixir Capital Ltd is Undervalued by 29.08% compared to the current share price 133.00

Last 5 Year EPS CAGR: 20.78%

*Investments are subject to market risks

Strength and Weakness

StrengthWeakness
  1. The stock has a high average ROCE of 15.08%, which is a positive sign.
  2. The company has higher reserves (23.23 cr) compared to borrowings (7.69 cr), indicating strong financial stability.
  3. The company has shown consistent growth in sales (14.38 cr) and profit (9.23 cr) over the years.
  1. The stock has a high average Working Capital Days of 371.00, which may not be favorable.
  2. The stock has a high average Cash Conversion Cycle of 7.00, which may not be favorable.

Stock Analysis

  • Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Elixir Capital Ltd:
    1. Net Profit Margin: 64.4%
      • Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
    2. ROCE: 39.68% (Industry Average ROCE: 18.4%)
      • ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
    3. ROE%: 32.22% (Industry Average ROE: 15.87%)
      • ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
    4. Interest Coverage Ratio (Post Tax): 14.43
      • Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
    5. Quick Ratio: 0.58
      • Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
    6. Stock P/E: 3.29 (Industry average Stock P/E: 63.72)
      • Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
    7. Total Debt / Equity: 0.48
      • Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
    The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
    Stock Rating:

About the Company - Qualitative Analysis

Elixir Capital Ltd. is a Public Limited Listed company incorporated on 30/11/1994 and has its registered office in the State of Maharashtra, India. Company's Corporate Identification Number(CIN) is L67190MH1994PLC083361 and registration number is 083361. Currently Company is involved in the business activities of Activities auxiliary to financial service activities. Company's Total Operating Revenue is Rs. 0.75 Cr. and Equity Capital is Rs. 5.80 Cr. for the Year ended 31/03/2024.
INDUSTRYADDRESSCONTACT
Finance & Investments58, Mittal Chambers, Mumbai Maharashtra 400021cosec@elixirequities.com
http://www.elixircapital.in
Management
NamePosition Held
Mr. Dipan MehtaChairman
Mrs. Radhika MehtaWholeTime Director & CFO
Mr. Suril ShahIndependent Director
Mr. Shail KapadiaIndependent Director

FAQ

What is the intrinsic value of Elixir Capital Ltd?

Elixir Capital Ltd's intrinsic value (as of 04 April 2025) is ₹142.14 — 6.87% higher the current market price of 133.00, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's 77.2 Cr. market cap, FY2025-2026 high/low of ₹351/78.0, reserves of 56 Cr, and liabilities of 122 Cr.

What is the Market Cap of Elixir Capital Ltd?

The Market Cap of Elixir Capital Ltd is 77.2 Cr..

What is the current Stock Price of Elixir Capital Ltd as on 04 April 2025?

The current stock price of Elixir Capital Ltd as on 04 April 2025 is 133.

What is the High / Low of Elixir Capital Ltd stocks in FY 2025-2026?

In FY 2025-2026, the High / Low of Elixir Capital Ltd stocks is ₹351/78.0.

What is the Stock P/E of Elixir Capital Ltd?

The Stock P/E of Elixir Capital Ltd is 3.29.

What is the Book Value of Elixir Capital Ltd?

The Book Value of Elixir Capital Ltd is 107.

What is the Dividend Yield of Elixir Capital Ltd?

The Dividend Yield of Elixir Capital Ltd is 0.94 %.

What is the ROCE of Elixir Capital Ltd?

The ROCE of Elixir Capital Ltd is 36.8 %.

What is the ROE of Elixir Capital Ltd?

The ROE of Elixir Capital Ltd is 50.0 %.

What is the Face Value of Elixir Capital Ltd?

The Face Value of Elixir Capital Ltd is 10.0.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Elixir Capital Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE